Marrone Bio Innovations Joins the Russell 2000 Index
DAVIS, Calif., June 25, 2018 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ:MBII) (MBI), a leading provider of bio-based pest management and plant health products for the agriculture, turf and ornamental and water treatment markets, today announced that the company’s common stock was added to the Russell 2000 Index after the market closed on June 22, 2018.
"We are pleased to have joined the Russell 2000 Index," said Dr. Pamela Marrone, Founder and CEO of Marrone Bio Innovations. "This addition marks an important milestone for MBI as we continue to grow, representing an opportunity to further increase our visibility within the investment community."
MBI is an industry leader in the rapidly growing market for biological crop protection and plant health, as its ability to discover and rapidly commercialize novel biological products is unmatched within the industry.
The Russell 2000 Index is a capitalization weighted index that measure the performance of the 2000 largest publicly held companies in the United States. FTSE Russell, a leading global index provider, determines membership for its equity indices primarily by objective, market-capitalization rankings and style attributes.
Indexes provided by FTSE Russell are widely used by investment professionals for index funds and as benchmarks for investment strategies. Approximately $16 trillion in assets are currently benchmarked to FTSE Russell Indexes.
Market analysis on the Russell Indexes is available at https://www.ftserussell.com/research-insights/russell-reconstitution.
About Marrone Bio Innovations
BIO WITH BITE.
Marrone Bio Innovations, Inc. (NASDAQ:MBII) strives to lead the movement to a more sustainable world through the discovery, development and promotion of biological products for crop protection and plant health. MBI’s effective and environmentally responsible pest management solutions help customers operate more sustainably while uniquely improving plant health and increasing crop yields. MBI’s currently available commercial products are Regalia®, Grandevo®, Venerate®, Majestene®, Haven® Stargus™ and Amplitude™, Zelto® and Zequanox®.
Marrone Bio Innovations is dedicated to pioneering smart biopesticide solutions that support a better tomorrow for both farmers, turf managers and consumers around the globe. For more information, please visit www.marronebio.com.
Marrone Bio Innovations Forward Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations and plans, including assumptions underlying such statements, are forward-looking statements, and should not be relied upon as representing MBI’s views as of any subsequent date. Such forward-looking statements such as the potential for the Russell 2000 and 3000 inclusion increasing our visibility are based on information available to the Company as of the date of this release and involve a number of risks and uncertainties, some beyond the Company's control, that could cause actual results to differ materially from those anticipated by these forward-looking statements. Additional information that could lead to material changes in MBI’s performance is contained in its filings with the SEC. MBI is under no obligation to, and expressly disclaims any responsibility to, update or alter forward-looking statements contained in this release, whether as a result of current information, future events or otherwise.
Marrone Bio Innovations Contacts:
Pam Marrone, CEO and Founder
Telephone: +1 (530) 750-2800
Email: Info@marronebio.com
MBI Investor Relations:
Greg Falesnik
Managing Director
MZ Group – MZ North America
Main: 949-385-6449
MBII@mzgroup.us
www.mzgroup.us
© 2018 GlobeNewswire, Inc. All Rights Reserved.
U.S. FDA Approves Gilead Sciences' (Nasdaq: GILD) Antiviral Veklury (remdesivir) for the Treatment of COVID-19
